Title of article :
Conversion surgery for hepatocellular carcinoma in the new era of targeted and immune checkpoint inhibitor therapies
Author/Authors :
zhao, lei shandong first medical university - shandong cancer hospital - department of hepatobiliary surgery, Jinan, China , zhao, haitao chinese academy of medical sciences - peking union medical college hospital - department ofliver surgery, Beijing, China
Abstract :
In the recent decade, systemic treatment of unresectable hepatocellular carcinoma (uHCC) with targeted and immune checkpoint inhibitors (ICIs) has achieved great progress. In the SHARP study conducted 12 years ago, sorafenib, the first systemic drug approved by the Food and Drug Administration (FDA) for advanced HCC, increased the median overall survival (mOS) from 7.9 to 10.7 months (1).
Journal title :
Hepatobiliary Surgery and Nutrition
Journal title :
Hepatobiliary Surgery and Nutrition
